Patent ID: 11913958
Assignee: ECS-PROGASTRIN SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  C  G

Claim 19:
20. A method for the in vitro diagnosis of lung cancer in a subject, said method comprising:
a) obtaining a biological sample from said subject,
b) measuring progastrin concentration in said biological sample by contacting said biological sample with a first progastrin-binding antibody, which binds to a first part of progastrin, wherein said first progastrin-binding antibody is a monoclonal antibody produced by the hybridoma deposited at the CNCM, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris CEDEX 15, France, on 27 Dec. 2016, under reference 1-5158, and
contacting said biological sample with a second progastrin-binding antibody, which binds to a second part of progastrin, wherein said second progastrin-binding antibody is a monoclonal antibody selected from the group consisting of:
a monoclonal antibody comprising a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, and a light chain comprising CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively,
a monoclonal antibody comprising a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, and a light chain comprising CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively,
a monoclonal antibody comprising a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively, and a light chain comprising CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21, respectively, and
a monoclonal antibody comprising a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, respectively, and a light chain comprising CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, respectively,

c) determining a reference concentration of progastrin in a reference sample,
d) comparing the concentration of progastrin in said biological sample with said reference concentration of progastrin,
e) detecting whether a lung cancer biomarker is present in said biological sample, and
f) diagnosing said subject with a lung cancer if said lung cancer biomarker is detected and if the concentration of progastrin in said biological sample is higher than said reference concentration of progastrin.